While the anticonvulsant mechanism(s) of action for CBGA is currently unknown, pharmacological activity at epilepsy-relevant targets has been characterized with inhibition of both GPR55 and Cav3.1 channels at therapeutically relevant concentrations (Anderson et al. 2021a, 2021band unpublished data). Here, CACNA1G is linked to epilepsy.